Alzheimer's research & therapy

Blood markers of Alzheimer's disease stages in a Chilean community and clinic group

Updated

Abstract

AUC = 0.88 for p-tau217 accurately distinguished Alzheimer's disease dementia from cognitively unimpaired individuals.

  • A progressive decline in the Aβ/Aβ ratio and increases in p-tau217 and GFAP were observed across the .
  • Higher levels of p-tau217 and NfL were linked to poorer cognitive, memory, and functional performance.
  • The combination of may help differentiate stages of Alzheimer's disease, although early-stage detection remains challenging.
  • These findings contribute to understanding plasma biomarkers in Alzheimer's disease within a Latin American cohort.

Simplified

Key numbers

0.88
AUC for p-tau217
Area under the curve for p-tau217 in classification models
318
Participants in the study
Total number of participants in the Chilean cohort
0.001
Significant differences in Aβ/Aβratio
p-value for differences in Aβ/Aβratio between groups

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Declarations. Ethics approval and consent to participate: The project was approved by the Ethics Committee of the Servicio de Salud Metropolitano Oriente (SSMO), Santiago (Chile), institution number IORG0006407. All participants had the capacity to provide informed consent in accordance with the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: TKK has consulted for Quanterix Corporation, SpearBio Inc., Neurogen Biomarking LLC., and Alzheon, has served on advisory boards for Siemens Healthineers and Neurogen Biomarking LLC., outside the submitted work. He has received in-kind research support from Janssen Research Laboratories, SpearBio Inc., and Alamar Biosciences, as well as meeting travel support from the Alzheimer’s Association and Neurogen Biomarking LLC., outside the submitted work. TKK has received royalties from Bioventix for the transfer of specific antibodies and assays to third party organizations. He has received honoraria for speaker/grant review engagements from the NIH, UPENN, UW‐Madison, the Cherry Blossom symposium, the HABS-HD/ADNI4 Health Enhancement Scientific Program, Advent Health Translational Research Institute, Brain Health conference, Barcelona‐Pittsburgh conference, the International Neuropsychological Society, the Icahn School of Medicine at Mount Sinai and the Quebec Center for Drug Discovery, Canada, all outside of the submitted work. TKK is an inventor on several patents and provisional patents regarding biofluid biomarker methods, targets and reagents/compositions, that may generate income for the institution and/or self should they be licensed and/or transferred to another organization. These include WO2020193500A1: Use of a ps396 assay to diagnose tauopathies; US 63/679,361: Methods to Evaluate Early-Stage Pre-Tangle TAU Aggregates and Treatment of Alzheimer’s Disease Patients; US 63/672,952: Method for the Quantification of Plasma Amyloid-Beta Biomarkers in Alzheimer’s Disease; US 63/693,956: Anti-tau Protein Antigen Binding Reagents; and 2450702-2: Detection of oligomeric tau and soluble tau aggregates. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The other authors report no conflicts of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free